73 related articles for article (PubMed ID: 18384719)
1. Use of step-section histopathology to evaluate 18F-fluorocholine PET sextant localization of prostate cancer.
Kwee SA; Thibault GP; Stack RS; Coel MN; Furusato B; Sesterhenn IA
Mol Imaging; 2008; 7(1):12-20. PubMed ID: 18384719
[TBL] [Abstract][Full Text] [Related]
2. Detection and localization of prostate cancer: correlation of (11)C-choline PET/CT with histopathologic step-section analysis.
Farsad M; Schiavina R; Castellucci P; Nanni C; Corti B; Martorana G; Canini R; Grigioni W; Boschi S; Marengo M; Pettinato C; Salizzoni E; Monetti N; Franchi R; Fanti S
J Nucl Med; 2005 Oct; 46(10):1642-9. PubMed ID: 16204714
[TBL] [Abstract][Full Text] [Related]
3. Localization of primary prostate cancer with dual-phase 18F-fluorocholine PET.
Kwee SA; Wei H; Sesterhenn I; Yun D; Coel MN
J Nucl Med; 2006 Feb; 47(2):262-9. PubMed ID: 16455632
[TBL] [Abstract][Full Text] [Related]
4. Prostate cancer localization with 18fluorine fluorocholine positron emission tomography.
Kwee SA; Coel MN; Lim J; Ko JP
J Urol; 2005 Jan; 173(1):252-5. PubMed ID: 15592091
[TBL] [Abstract][Full Text] [Related]
5. Prostate cancer: sextant localization with MR imaging, MR spectroscopy, and 11C-choline PET/CT.
Testa C; Schiavina R; Lodi R; Salizzoni E; Corti B; Farsad M; Kurhanewicz J; Manferrari F; Brunocilla E; Tonon C; Monetti N; Castellucci P; Fanti S; Coe M; Grigioni WF; Martorana G; Canini R; Barbiroli B
Radiology; 2007 Sep; 244(3):797-806. PubMed ID: 17652190
[TBL] [Abstract][Full Text] [Related]
6. 11C-choline positron emission tomography/computerized tomography for tumor localization of primary prostate cancer in comparison with 12-core biopsy.
Martorana G; Schiavina R; Corti B; Farsad M; Salizzoni E; Brunocilla E; Bertaccini A; Manferrari F; Castellucci P; Fanti S; Canini R; Grigioni WF; D'Errico Grigioni A
J Urol; 2006 Sep; 176(3):954-60; discussion 960. PubMed ID: 16890665
[TBL] [Abstract][Full Text] [Related]
7. Influence of trigger PSA and PSA kinetics on 11C-Choline PET/CT detection rate in patients with biochemical relapse after radical prostatectomy.
Castellucci P; Fuccio C; Nanni C; Santi I; Rizzello A; Lodi F; Franceschelli A; Martorana G; Manferrari F; Fanti S
J Nucl Med; 2009 Sep; 50(9):1394-400. PubMed ID: 19690023
[TBL] [Abstract][Full Text] [Related]
8. C-11 choline PET/CT imaging for differentiating malignant from benign prostate lesions.
Li X; Liu Q; Wang M; Jin X; Liu Q; Yao S; Liu S; Li J
Clin Nucl Med; 2008 Oct; 33(10):671-6. PubMed ID: 18806565
[TBL] [Abstract][Full Text] [Related]
9. Comparison of triple-negative and estrogen receptor-positive/progesterone receptor-positive/HER2-negative breast carcinoma using quantitative fluorine-18 fluorodeoxyglucose/positron emission tomography imaging parameters: a potentially useful method for disease characterization.
Basu S; Chen W; Tchou J; Mavi A; Cermik T; Czerniecki B; Schnall M; Alavi A
Cancer; 2008 Mar; 112(5):995-1000. PubMed ID: 18098228
[TBL] [Abstract][Full Text] [Related]
10. Per-sextant localization and staging of prostate cancer: correlation of imaging findings with whole-mount step section histopathology.
Graser A; Heuck A; Sommer B; Massmann J; Scheidler J; Reiser M; Mueller-Lisse U
AJR Am J Roentgenol; 2007 Jan; 188(1):84-90. PubMed ID: 17179349
[TBL] [Abstract][Full Text] [Related]
11. Preoperative detection of prostate cancer: a comparison with 11C-choline PET, 18F-fluorodeoxyglucose PET and MR imaging.
Watanabe H; Kanematsu M; Kondo H; Kako N; Yamamoto N; Yamada T; Goshima S; Hoshi H; Bae KT
J Magn Reson Imaging; 2010 May; 31(5):1151-6. PubMed ID: 20432351
[TBL] [Abstract][Full Text] [Related]
12. 18F-FDOPA PET and PET/CT accurately localize pheochromocytomas.
Imani F; Agopian VG; Auerbach MS; Walter MA; Imani F; Benz MR; Dumont RA; Lai CK; Czernin JG; Yeh MW
J Nucl Med; 2009 Apr; 50(4):513-9. PubMed ID: 19289420
[TBL] [Abstract][Full Text] [Related]
13. Prostate cancer detection: comparison of T2-weighted imaging, diffusion-weighted imaging, proton magnetic resonance spectroscopic imaging, and the three techniques combined.
Chen M; Dang HD; Wang JY; Zhou C; Li SY; Wang WC; Zhao WF; Yang ZH; Zhong CY; Li GZ
Acta Radiol; 2008 Jun; 49(5):602-10. PubMed ID: 18568549
[TBL] [Abstract][Full Text] [Related]
14. [(11)C]Choline positron emission tomography/computed tomography for staging and restaging of patients with advanced prostate cancer.
Tuncel M; Souvatzoglou M; Herrmann K; Stollfuss J; Schuster T; Weirich G; Wester HJ; Schwaiger M; Krause BJ
Nucl Med Biol; 2008 Aug; 35(6):689-95. PubMed ID: 18678354
[TBL] [Abstract][Full Text] [Related]
15. The detection of bone metastases in patients with high-risk prostate cancer: 99mTc-MDP Planar bone scintigraphy, single- and multi-field-of-view SPECT, 18F-fluoride PET, and 18F-fluoride PET/CT.
Even-Sapir E; Metser U; Mishani E; Lievshitz G; Lerman H; Leibovitch I
J Nucl Med; 2006 Feb; 47(2):287-97. PubMed ID: 16455635
[TBL] [Abstract][Full Text] [Related]
16. The Role of 18F-FDG PET/CT in the evaluation of Ascites of Undetermined Origin.
Zhang M; Jiang X; Zhang M; Xu H; Zhai G; Li B
J Nucl Med; 2009 Apr; 50(4):506-12. PubMed ID: 19289438
[TBL] [Abstract][Full Text] [Related]
17. Comparative effectiveness of [(18) F]-fluorocholine PET-CT and pelvic MRI with diffusion-weighted imaging for staging in patients with high-risk prostate cancer.
Pinaquy JB; De Clermont-Galleran H; Pasticier G; Rigou G; Alberti N; Hindie E; Mokrane Y; Fernandez P
Prostate; 2015 Feb; 75(3):323-31. PubMed ID: 25393215
[TBL] [Abstract][Full Text] [Related]
18. The value of quantifying 18F-FDG uptake in thyroid nodules found incidentally on whole-body PET-CT.
Bogsrud TV; Karantanis D; Nathan MA; Mullan BP; Wiseman GA; Collins DA; Kasperbauer JL; Strome SE; Reading CC; Hay ID; Lowe VJ
Nucl Med Commun; 2007 May; 28(5):373-81. PubMed ID: 17414887
[TBL] [Abstract][Full Text] [Related]
19. Usefulness of MRI-assisted metabolic volumetric parameters provided by simultaneous (18)F-fluorocholine PET/MRI for primary prostate cancer characterization.
Kim YI; Cheon GJ; Paeng JC; Cho JY; Kwak C; Kang KW; Chung JK; Kim EE; Lee DS
Eur J Nucl Med Mol Imaging; 2015 Jul; 42(8):1247-56. PubMed ID: 25759164
[TBL] [Abstract][Full Text] [Related]
20. Sextant localization of prostate cancer: comparison of sextant biopsy, magnetic resonance imaging and magnetic resonance spectroscopic imaging with step section histology.
Wefer AE; Hricak H; Vigneron DB; Coakley FV; Lu Y; Wefer J; Mueller-Lisse U; Carroll PR; Kurhanewicz J
J Urol; 2000 Aug; 164(2):400-4. PubMed ID: 10893595
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
